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HIF = hypoxia-inducible factor-1; VHL = von Hippel–Lindau.
Available online http://breast-cancer-research.com/content/3/5/313
Introduction
Oxygen homeostasis is of critical importance for all mam-
malian cells, because too much oxygen results in toxicity
and too little impairs metabolism. Maintenance of oxygen
levels within tight limits is essential throughout life, but is
particularly important during periods of rapid cellular prolif-
eration, both in normal development and neoplasia.
Control of oxygen levels in the tissues of an animal occurs
through a combination of gene regulatory, biochemical
and physiological mechanisms. The present review
focuses on the considerable advances that have been
made during the past decade in our understanding of the
gene regulatory processes involved.
An important insight into the molecular basis of oxygen
homeostasis arose through studies on the control of ery-
thropoietin expression. The hormone erythropoietin is
central to the feedback loop that regulates tissue oxygena-
tion. By increasing red cell production in response to tissue
hypoxia, erythropoietin increases tissue oxygen delivery,
thereby mitigating the original stimulus. Interestingly, ery-
thropoietin levels can also be increased by iron chelation.
Erythropoietin levels are principally controlled by transcrip-
tional regulation of erythropoietin gene expression by a
hypoxically regulated enhancer that is located 3′  to the
gene. It was initially considered likely that regulation of ery-
thropoietin gene transcription by hypoxia represents a
special case. However, early studies following the identifica-
tion of the erythropoietin hypoxically regulated enhancer
demonstrated that it was a paradigm for a central mecha-
nism of oxygen-regulated gene expression operative in
most, if not all, cell types [1]. Subsequently, HIF was identi-
fied as the novel transcription factor that operates this
enhancer; it too was found to be widely expressed and
operative [2,3]. Although the activity of many transcription
factors, including fos, jun and p53, is affected by tissue oxy-
genation, thereby influencing gene regulation, it has become
increasingly apparent that HIF is the dominant transcription
factor that affects gene expression by oxygen levels.
Hypoxia-inducible factor-1, and the hypoxia
inducible factor-1 system
HIF is a heterodimer of α and β subunits, each of which
exist as gene families, and all of which are members of the
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PAS superfamily of transcription factors [3]. The β sub-
units (also known as aryl hydrocarbon receptor nuclear
translocators) are constitutively nuclear proteins that also
have roles in transcriptional responses to xenobiotic
agents. In contrast, the α subunits have to date only been
shown to take part in gene regulatory responses to
hypoxia and iron chelation.
Following the recognition that the erythropoietin enhancer
(to which HIF binds) was widely operative and that HIF
itself was widely expressed, it was logical to explore the
activity of this mechanism in the hypoxic regulation of
genes other than the erythropoietin gene. Initial studies
focused on genes with known functions that were
expected to be regulated by oxygen levels. Those studies
implicated HIF in the regulation of such diverse processes
as glycolysis, glucose transport and angiogenesis (for
review [4]). A striking concordance between patterns of
gene expression that have classically been associated
with cancer and the range of genes induced by HIF activa-
tion in cultured cells was noted [5]. More recently, un-
prejudiced approaches such as differential display
polymerase chain reaction, screening of gene arrays and
studies in HIF-deficient mutant cells [6,7] have broadened
the number of processes that are known to be regulated
by this complex. Interestingly, HIF target genes with
antiproliferative and proapoptotic actions have thus been
identified. Given the combinatorial nature of gene regula-
tion, it is clear that the genes that are actually controlled by
HIF may vary from cell type to cell type, as indeed is exem-
plified by the tissue specificity of erythropoietin expression.
Regulation of the hypoxia inducible factor-1
complex occurs at many levels
Initial reports suggested that HIF subunit mRNA levels
were regulated by hypoxia. In cell lines such effects are
modest and insignificant compared with post-translational
mechanisms, but the situation may be different in some
primary cells.
When oxygen tension is lowered, HIF α subunits are stabi-
lized, translocate to the nucleus and dimerize with a
β subunit. The HIF complex binds hypoxia response ele-
ments, recruits the coactivator CREB-binding protein/P300
via the carboxyl-terminus of the α subunit [8] and activates
transcription of a range of genes. Although many steps in
this pathway are sensitive to variation in oxygen levels, the
dominant mode of regulation is through oxygen-dependent
destruction of HIF α subunits by the ubiquitin-proteasome
pathway [9,10]. This destruction is mediated by a ubiquitin
E3 ligase complex, in which the von Hippel–Lindau (VHL)
tumour suppressor protein recognizes and binds oxygen-
dependent destruction domain(s) in the HIF α subunits
[11,12]. This recognition of HIF α subunits in normoxia
has recently been shown [13,14] to be conditional on
iron-dependent and oxoglutarate-dependent enzymatic
post-translational hydroxylation of critical prolyl residues. It
is known that this family of dioxygenases use superoxide
as a catalytic intermediate, and it is possible that redox
agents that are known to influence HIF activation act by
modulating enzymatic activity.
As yet it remains unclear how many other aspects of gene
regulation can be explained by such enzymatic modifica-
tion. In the context of hypoxia it could underlie the concor-
dant regulation of all activating functions of HIF, including
coactivator recruitment by the carboxyl-terminus and
nuclear localization. It might also be responsible for influ-
ences on mRNA stability, which appear to underlie other
forms of gene regulation by hypoxia. Furthermore, the dis-
covery of this mechanism may have general implications
for our understanding of the function of PEST domains,
which are known to be associated with protein instability.
The direct pathway outlined above operates in a complex
intracellular environment, and increasing evidence exists
for direct or indirect sensitivity to other influences. For
example, there are reports of activation of HIF in response
to inactivation of a number of different tumour suppressor
genes, in response to activation of several different onco-
genes and in response to activation of diverse growth
factor pathways (see below).
Hypoxia inducible factor-1 activation in cancer
It is now recognized that HIF activation in cancer can
occur both in response to microenvironmental tumour
hypoxia and as a result of genetic mechanisms.
Use of experimental tumours with and without an intact
HIF system [15] showed the HIF-dependent regional
expression of HIF regulated endogenous genes, particu-
larly in perinecrotic areas. Studies of xenografts that
express a stably integrated, hypoxically regulated,
enhancer dependent reporter gene [16] also showed
regional activation. Importantly, the use of comet assays
provided further evidence that these regions were indeed
hypoxic. Immunostaining for the α subunit can be used to
identify the extent of HIF activation in natural tumours,
because HIF α stabilization is necessary for formation of
active HIF. Although there may be threshold effects and
the short half-life of this molecule requires immense care
with fixation, HIF α chains are observed within regions in
over half of all solid malignant tumours, most commonly in
perinecrotic areas [17,18].
Although rapidly proliferating cells will outstrip the available
oxygen supply, with consequent hypoxia and HIF activation,
there is evidence for more direct links between proliferation
and amplification of the HIF response. Thus, activation of
several oncogenes (Ha-ras, myc and src), loss of tumour
suppressor functions (p53, PTEN) and exposure to differ-
ent growth factors (insulin, insulin-like growth factor-1 andc
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-2, angiotensin II) have been reported to increase HIF activ-
ity in normoxia and hypoxia, with a preserved hypoxic
response [19,20]. The proposed mechanisms of amplifica-
tion differ. Expression of v-src increases HIF-1 α protein
and target gene activation, an effect that appears to involve
an increase in HIF-1 α mRNA [21]. Effects that are modu-
lated via AKT (protein kinase B) and phosphatidylinositol 3
kinase are believed to underlie the actions of PTEN [22,23]
and Ha-ras [24,25], respectively, although these actions
may not be direct. p42/p44 Mitogen-activated protein
kinase has been implicated in HIF α phosphorylation, and
activation of mitogen-activated protein kinase promotes
transcriptional activation by HIF [26]. Wild-type p53 has
been reported to promote MDM2-mediated ubiquitylation
and degradation of HIF-1 α in at least some circumstances
[27]. In contrast c-myc acts directly on the HIF responsive
enhancer elements [28].
In VHL syndrome a mutant VHL allele is inherited. Tumours
in which the second VHL allele is defective develop in a
limited range of tissues. Cells from these tumours show
constitutive HIF activation as a result of failure of normoxic
recognition, and thus ubiquitylation, by the VHL E3 ligase
complex. Similarly, spontaneous renal carcinoma cell lines
that lack the VHL tumour suppressor protein also show
constitutive activation of the HIF system. Experimental re-
introduction of a wild-type VHL gene into these cells
results in reduced tumour growth. Thus, in at least some
cell types constitutive activation of the HIF system is not
only tolerated, but confers advantages for tumour cell
growth. Conversely, as described above, it is clear that the
HIF pathway remains sensitive to oxygen in a very wide
range of cancer cells. Because HIF activation offers poten-
tial advantages to proliferating cells, this suggests that bal-
ancing pressures prevent maximal HIF activation. The
known ability of HIF to activate antiproliferative and
proapoptotic genes provides a plausible selective pressure
against constitutive HIF activation in many tumours.
Variable effects have been demonstrated in experimental
tumours. In studies that compared mouse hepatoma cells
with wild-type or defective HIF pathways, as a result of
HIF-1 β deficiency, the mutant cells showed both reduced
angiogenesis and reduced tumour growth [15]. Studies in
HIF-1 α-deficient mouse embryonic stem cells have in one
case yielded similar results [29], but other studies showed
enhanced growth in the deficient cells that were resistant
to hypoxia-induced apoptosis [30]. In another study [31]
tumours derived from HIF-1 α-deficient fibroblasts grew at
a slower rate than their wild-type counterparts, despite
similar angiogenic development.
Hypoxia, hypoxia inducible factor-1 and
tumour prognosis
The extent of tumour hypoxia is known to correlate with
poor prognosis [32]. Hypoxia appears to be a direct
marker of tumour aggressiveness, but ischaemic areas are
protected against standard therapies, receiving a lower
dose of systemically administered chemotherapeutic
agents and being more radioresistant as a result of
reduced generation of oxygen radicals.
Knowledge of the relationship between HIF activity and
tumour prognosis is currently in its infancy. Immunodetec-
tion of HIF α chains now provides a route to quantify and
localize HIF activation. Caution is required, however,
because the rapid modulation of HIF α protein levels in
response to changes in tissue oxygenation means that dif-
ferences in the handling of clinical specimens between the
time of surgical cross-clamping and fixation can result in
spurious upregulation or downregulation of the amount
detected. Despite these concerns, in one study of breast
cancer [33] positive staining for HIF-1 α appeared to be
associated with more aggressive tumours. However, in a
study of non-small-cell lung cancers [34] survival was
better in patients with HIF-positive tumours than in those
with HIF-negative tumours. It is not yet clear whether
these observations relate to fundamental differences in the
role of HIF in the biology of these tumour types, or
whether there are other explanations for them.
Opportunities for therapeutic intervention
The observed upregulation of HIF in many cancers, the
role of HIF in upregulation of angiogenic growth factors,
and the role of angiogenic growth factors in tumour
growth suggests that downregulating the HIF system
could potentially be beneficial in tumour therapy. The
xenograft experiments described above established that,
in some circumstances, blocking the HIF response can
have beneficial effects on tumour angiogenesis and
growth [15,29]. Manoeuvres such as complete suppres-
sion of HIF α or β chain expression in all tumour cells are
clearly difficult to apply clinically. However, a recent study
that used peptides that block the interaction between the
HIF-1 α carboxyl-terminus and the transcriptional coactiva-
tor p300 [35] demonstrated reduction in growth and
angiogenesis in tumours derived from breast and colon
carcinoma cells. Equally, the recent identification of the
key role of enzymatic modification of critical prolyl residues
in HIF α chains provides hope that small molecule modula-
tors of enzymatic activity may have therapeutic value,
although it will probably be easier to identify enzyme
inhibitors than potentiators.
It is important to sound two notes of caution, however.
First, HIF downregulation will be detrimental in those cir-
cumstances in which the proapoptotic and antiproliferative
effects predominate (although strategies to upregulate HIF,
such as the use of peptides or enzyme inhibitors that block
HIF degradation, might be applied to advantage in these
circumstances). Second, the central role of the HIF system
in the normal physiological adaptive responses to hypoxia
Available online http://breast-cancer-research.com/content/3/5/313suggests that manipulation of this system would have to be
confined in some way to the tumour, if deleterious systemic
side effects, such as anaemia, are to be avoided.
An alternative approach being investigated uses the acti-
vation of HIF in many tumours to direct therapeutic gene
expression following introduction of gene therapy cas-
settes controlled by hypoxically regulated enhancers.
Again, care will be needed to prevent unwanted therapeu-
tic gene expression in areas of physiological hypoxia, such
as the renal medulla.
Conclusion
The HIF system has a central role in physiological adapta-
tion to hypoxia, and is frequently activated in tumours.
Activation may occur simply as an expected consequence
of microenvironmental hypoxia. However, a variety of
genetic mechanisms that induce proliferation and are
active in various tumours appear to sensitize the HIF
system. It is therefore increasingly likely that there is a
direct link between mechanisms that stimulate prolifera-
tion, thereby incurring an obligate energy cost, and this
important system. In some tissues constitutive activation
of the HIF system by inactivation of the VHL tumour sup-
pressor protein is intimately linked to tumourigenesis.
The precise consequences of HIF activation vary between
tumour types, with a balance between protumour and anti-
tumour effects being manifest. In many tumours, however,
it is likely that modulation of the HIF system or use of the
upregulated HIF activity could be used to therapeutic
advantage.
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